Summary paper on the 2023 European Association of Urology guidelines on the management of non-neurogenic male lower urinary tract symptoms
Context Lower urinary tract symptoms (LUTS) are common, often bothersome, and have
multifactorial aetiology. Objective To present a summary of the 2023 version of the European …
multifactorial aetiology. Objective To present a summary of the 2023 version of the European …
[HTML][HTML] Current treatment for benign prostatic hyperplasia
Current Treatment for Benign Prostatic Hyperplasia - PMC Back to Top Skip to main content NIH
NLM Logo Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation …
NLM Logo Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation …
A guide to medications inducing salivary gland dysfunction, xerostomia, and subjective sialorrhea: a systematic review sponsored by the world workshop on oral …
A Wolff, RK Joshi, J Ekström, D Aframian… - Drugs in R&d, 2017 - Springer
Background Medication-induced salivary gland dysfunction (MISGD), xerostomia (sensation
of oral dryness), and subjective sialorrhea cause significant morbidity and impair quality of …
of oral dryness), and subjective sialorrhea cause significant morbidity and impair quality of …
Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment
EA Gormley, DJ Lightner, M Faraday… - The Journal of …, 2015 - auajournals.org
Purpose: The purpose of this guideline amendment, herein referred to as the amendment, is
to incorporate relevant newly published literature to better provide a clinical framework for …
to incorporate relevant newly published literature to better provide a clinical framework for …
[HTML][HTML] Efficacy and tolerability of mirabegron compared with antimuscarinic monotherapy or combination therapies for overactive bladder: a systematic review and …
Background Mirabegron is an established treatment alternative to antimuscarinic therapy for
patients with overactive bladder (OAB), as shown by efficacy and tolerability data from phase …
patients with overactive bladder (OAB), as shown by efficacy and tolerability data from phase …
Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β 3-adrenoceptor agonist, in overactive bladder
CR Chapple, SA Kaplan, D Mitcheson, J Klecka… - European urology, 2013 - Elsevier
BACKGROUND: Despite several antimuscarinic treatment options for overactive bladder
(OAB), there is still a need for distinct treatment approaches to manage this condition …
(OAB), there is still a need for distinct treatment approaches to manage this condition …
[HTML][HTML] Persistence and adherence with mirabegron versus antimuscarinic agents in patients with overactive bladder: a retrospective observational study in UK …
Background Persistence with antimuscarinic therapy in overactive bladder (OAB) is poor, but
may be different for mirabegron, aβ 3-adrenoceptor agonist with a different adverse event …
may be different for mirabegron, a
Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability
CR Chapple, L Cardozo, VW Nitti… - Neurourology and …, 2014 - Wiley Online Library
Aims Mirabegron, the first β 3‐adrenoceptor agonist to enter clinical practice, has a different
mechanism of action from antimuscarinic agents. This review presents data on the efficacy …
mechanism of action from antimuscarinic agents. This review presents data on the efficacy …
Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison
K Maman, S Aballea, J Nazir, K Desroziers, ME Neine… - European urology, 2014 - Elsevier
Context Overactive bladder (OAB) treatment guidelines recommend antimuscarinics as first-
line pharmacologic therapy. Mirabegron is a first-in-classβ 3-adrenoceptor agonist licensed …
line pharmacologic therapy. Mirabegron is a first-in-class